Synthesis and characterisation of a ruthenocenoyl bioconjugate with the cyclic octapeptide octreotate

Synthesis and Characterization of the Azido‐Functionalized Ruthenocene Analogue [TpmRu(p‐N3C6H4)Tp]Cl and Its Attachment to Biomolecules by Copper‐Catalyzed Azide–Alkyne Cycloaddition

“…Although half sandwich [TpmRu(COD)Cl]Cl can be accessed by heating a mixture of Tpm and [RuCl 2 (COD)] x in ethanol for 7 h, [17] comparable yields of pure TpRu(COD)Cl are accessible in 2 h by reaction of [RuH(udmh) 3 (COD)][X] (X = PF 6 , BPh 4 ; udmh = N,N-dimethylhydrazine) [18] with a Tp transfer agent and subsequent addition of tetrachloromethane. [19,20] Thus, the functionalized half sandwich compound TpЈRu(COD)Cl (1) was synthesized by modification of literature preparations for TpRu(COD)Cl.…”

“…[1] One class of compounds frequently employed for such purposes due to their high stability, facile derivatization, and their suitability as electrochemical probes, are metallocenes, in particular ferrocene Cp 2 Fe (Cp = cyclopentadienyl), [2][3][4] and, to a much lesser extent, ruthenocene (Cp 2 Ru). [5,6] Remarkably, the use of analogues of these compounds, whether homoor heteroleptic, has not been investigated to any serious extent. Accordingly, we have been interested in employing analogues of group 8 metallocenes in bioorganometallic applications.…”

A Novel Organometallic ReI Complex with Favourable Properties for Bioimaging and Applicability in Solid‐Phase Peptide Synthesis

“…[1] A useful strategy to enhance the bioavailability and target specificity of potentially active compounds is to link them to biological vectors such as peptides, carbohydrates or hormones. [2] In the past we have reported on the successful synthesis of peptide bioconjugates for such purposes, in which we have used a range of different transition metal complexes based on iron, [3][4][5] copper, [6] zinc, [6] cobalt, [4,[7][8][9] ruthenium, [10,11] rhenium, [12] platinum [12] and molybdenum. [13] One major advantage of peptide-based conjugates is their variability.…”

Conjugation of a Ru(II) Arene Complex to Neomycin or to Guanidinoneomycin Leads to Compounds with Differential Cytotoxicities and Accumulation between Cancer and Normal Cells

“…[15][16] Among such modifications, derivatization of non-leaving ligands with a carrier molecule has tremendous potential to generate selective, less toxic metallodrugs. The potential of this targeted strategy is particularly promising when metal complexes, either organometallic or classical coordination compounds, are attached to biomolecules [17][18][19][20][21][22][23][24] whose receptors are overexpressed on the membrane of tumoral cells [25][26][27][28] or to organic molecules with high affinity with a given biological target (proteins or nucleic acids). 29 Such differences in cytotoxic activity for each compound in a particular cell line, either normal or tumoral, could be interpreted in terms of cell uptake and accumulation efficiency.…”

“…15,16 Moreover, modification of the non-leaving ligands allows the metal complex to be anchored to a "tumor-targeting device" such as receptor-binding peptides, folic acid or estrogens. [17][18][19][20][21][22][23][24] This targeted strategy has a tremendous potential in the development of more efficient, less toxic, selective metallodrugs in chemotherapy because receptors for these carrier molecules are over-expressed in the membrane of tumoral cells. [25][26][27][28] Another strategy to improve efficiency of a metal-based drug is to increase its affinity with its ultimate biological target.…”